Periodic Reporting for period 1 - GC T Subsets (T cell subsets underlying the rise, fall and recall of the Germinal Center)
Okres sprawozdawczy: 2022-09-01 do 2025-02-28
We have previously shown that GC-resident helper T cells can acquire regulatory phenotypes that shape the quality of B cells, impacting antibody diversity and functionality. These findings highlight the importance of understanding how distinct T cell subsets mediate either help or suppression within GCs, driving the differentiation of B cells into high-affinity plasma cells or long-lived memory B cells. This knowledge has profound implications for developing vaccines aimed at eliciting broadly neutralizing antibodies (bnAbs), essential for combating pathogens such as HIV, influenza, and Plasmodium. Additionally, elucidating the molecular pathways governing helper and suppressive T cell functions in GCs provides valuable insights into autoimmune diseases and chronic inflammation, informing the development of T cell-based therapeutic strategies.
Current approaches fail to address the multifaceted roles of T cell subsets within the GC. This ERC StG project aims to uncover the determinants of T cell heterogeneity and their molecular mechanisms, with a specific focus on their impact on B cell quality and antibody functionality.
A novel method for generating monoclonal TCR knock-in mice was developed using AAV and CRISPR/Cas9 genome editing. This transformative approach offers a more efficient, precise, and rapid strategy for creating functional monoclonal TCR mouse models, ensuring physiological TCR expression and accurate T cell differentiation. This significant improvement over traditional transgenic techniques has facilitated the expedited generation of multiple models critical to this project.
Additionally, a GC-driven platform for optimizing therapeutic monoclonal antibodies was established. Leveraging insights into somatic hypermutation and clonal selection within GCs gained during the project period, this system enables the efficient generation of high-affinity therapeutic antibodies targeting challenging antigens.
Overall, this phase has advanced the understanding of T and B cell biology while implementing innovative methodologies grounded in insights gained during this period.